RT Journal Article
SR Electronic
T1 Protocol for a multicentre randomised controlled trial of STeroid Administration Routes For Idiopathic Sudden sensorineural Hearing loss: the STARFISH trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.08.09.23293918
DO 10.1101/2023.08.09.23293918
A1 Smith, Matthew E
A1 Knappet, Rachel
A1 Vickers, Debi
A1 White, David
A1 Schramm, Chris J
A1 Mehta, Samir
A1 Sun, Yongzhong
A1 Watkins, Ben
A1 Chadburn, Marie
A1 Jarrett, Hugh
A1 James, Karen
A1 Roberts, Tracy
A1 Bance, Manohar L
A1 INTEGRATE, the UK ENT Trainee Research Network
A1 Tysome, James R
YR 2023
UL http://medrxiv.org/content/early/2023/08/15/2023.08.09.23293918.abstract
AB Idiopathic sudden sensorineural hearing loss (ISSNHL) is the rapid onset of reduced hearing due to loss of function of the inner ear or hearing nerve of unknown aetiology. Evidence supports improved hearing recovery with early steroid treatment, via oral, intravenous, intratympanic or a combination of routes. The STARFISH trial aims to identify the most clinically and cost-effective route of administration of steroids as first-line treatment for ISSNHL.STARFISH is a pragmatic, multicentre, assessor-blinded, three-arm intervention, superiority randomised controlled trial (1:1:1) with an internal pilot (ISRCTN10535105, IRAS 1004878). 525 participants with ISSNHL will be recruited from approximately 75 UK Ear, Nose and Throat units.STARFISH will recruit adults with sensorineural hearing loss averaging 30dBHL or greater across three contiguous frequencies (confirmed via pure tone audiogram), with onset over a ≤3-day period, within four weeks of randomisation. Participants will be randomised to 1) oral prednisolone 1mg/Kg/day up to 60mg/day for 7 days; 2) intratympanic dexamethasone: three intratympanic injections 3.3mg/ml or 3.8mg/ml spaced 7±2 days apart; or 3) combined oral and intratympanic steroids.The primary outcome will be absolute improvement in pure tone audiogram average at 12- weeks following randomisation (0.5, 1.0, 2.0 and 4.0kHz). Secondary outcomes at 6 and 12 weeks will include: Speech, Spatial and Qualities of hearing scale, high frequency pure tone average thresholds (4.0, 6.0 and 8.0kHz), Arthur Boothroyd speech test, Vestibular Rehabilitation Benefit Questionnaire, Tinnitus Functional Index, adverse events and optional weekly online speech and pure tone hearing tests.A health economic assessment will be performed, and presented in terms of incremental cost effectiveness ratios, and cost per quality-adjusted life-year.Primary analyses will be by intention-to-treat. Oral prednisolone will be the reference. For the primary outcome, the difference between group means and 97.5% confidence intervals at each time-point will be estimated via a repeated measures mixed-effects linear regression model.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialISRCTN10535105Funding StatementThis work was funded by a grant from UK NIHR Health Technology Assessment, HTA Reference Number: NIHR131528. The grant was awarded to JRT and MES as joint lead applicants, with co-applicants CS, DV, DW, HJ, SM, RK, MB and TR: https://fundingawards.nihr.ac.uk/award/NIHR131528. The funder provided feedback on study design at an early stage, but has not had a role in protocol development or publication. The primary Sponsor for the study is the University of Birmingham, Edgbaston, Birmingham, B15 2TT. This research was supported by the NIHR Cambridge Biomedical Research Centre.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NRES (London - Harrow Research Ethics Committee)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesNo datasets were generated or analysed during the current study. All relevant data from this study will be made available upon study completion.